FoundationFocus CDxBRCA
FoundationFocus™ CDxBRCA LOH is an assay that uses next-generation sequencing (NGS) for qualitative detection of BRCA1 and BRCA2 sequence alterations and genomic loss of heterozygosity (LOH) from formalin-fixed, paraffin-embedded (FFPE) ovarian tumor tissue. Results of the test are used as an aid in identifying ovarian cancer patients with deleterious tumor BRCA variants (tBRCA-positive), who may be eligible for treatment with Rubraca (rucaparib).
Positive homologous recombination deficiency (HRD) status (defined as tBRCA-positive or LOH high) in ovarian cancer patients is associated with improved progression-free survival (PFS) from Rubraca maintenance therapy. See the RUBRACA product label for information about guiding therapy in specific clinical circumstances. This test is to be performed at Foundation Medicine, Inc., a single laboratory site, located at 150 Second Street, Cambridge, MA 02141.
- This test is used to find BRCA1 and BRCA2 alterations in FFPE ovarian tumor tissue
- The test is used in patients for whom Rubraca (rucaparib) is being considered
No reportable variants were identified (Negative for mutation analyzed)
Formalin-fixed paraffin embedded (FFPE) tumor tissue specimens.
- Lung Cancer. 2014 Mar;83(3):329-33. [PMID: 24439568]
- J Clin Pathol. 2013 May;66(5):381-5. [PMID: 23386666]
- Diagn Mol Pathol 22, 138-43 (2013). [PMID: 23846439]
- Clin Oncol 34:3518-3528, 2016. [PMID: 27573653]
- J Clin Oncol. 2009 Jun 20;27(18):2962-9. [PMID: 19364966]
- Cancer Discov. 2018 Mar;8(3):OF4. doi: 10.1158/2159-8290.CD-NB2017-182. [PMID: 29339360]